Research Report Screener Results

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 10-Feb-2010
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 10 of 20)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
8-Feb-10 Standard & Poor's Quantitative Report N/A NeurogesX Inc 6 $25 View Abstract
8-Feb-10 Market Edge N/A Market Edge Equity Research Report 4 $10 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Industry Value Graph: ADLR , BIOD , INFI , JAV , KERX , MBRK , NGSX , SNTA -- DRUGS 3 $4 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Value Graph: NEUROGESX -- NGSX 1 $4 View Abstract
31-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: NEUROGESX INC 5 $25 View Abstract
29-Jan-10 Jefferson Research N/A Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of NEUROGESX INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. 11 $20 View Abstract
28-Jan-10 Roth Capital Partners, Inc. Research Department Morning Call Summary 16 $50 View Abstract
28-Jan-10 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino PhD Raising Price Target On NeurogesX As Qutenza Launch Approaches 7 $25 View Abstract
24-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: NEUROGESX INC 5 $25 View Abstract
17-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: NEUROGESX INC 5 $25 View Abstract
Next 10

Brokerage Reports (Showing 1 to 6 of 6)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
28-Jan-10 Roth Capital Partners, Inc. Research Department Morning Call Summary 16 $50 View Abstract
28-Jan-10 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino PhD Raising Price Target On NeurogesX As Qutenza Launch Approaches 7 $25 View Abstract
4-Jan-10 Roth Capital Partners, Inc. Research Department Morning Call Summary 13 $50 View Abstract
4-Jan-10 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino PhD A 2010 Catalyst Calendar Of Roth Biotech Coverage 8 $25 View Abstract
20-Mar-09 Roth Capital Partners, Inc. N/A Morning Call Summary 13 $60 View Abstract
20-Mar-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino Q4 EPS Beats Estimates, And Qutenza Recommended For Approval In Europe 6 $30 View Abstract

Independent Reports (Showing 1 to 10 of 14)

Release
Date Contributor Author Title Pages Price More Info
8-Feb-10 Standard & Poor's Quantitative Report N/A NeurogesX Inc 6 $25 View Abstract
8-Feb-10 Market Edge N/A Market Edge Equity Research Report 4 $10 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Industry Value Graph: ADLR , BIOD , INFI , JAV , KERX , MBRK , NGSX , SNTA -- DRUGS 3 $4 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Value Graph: NEUROGESX -- NGSX 1 $4 View Abstract
31-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: NEUROGESX INC 5 $25 View Abstract
29-Jan-10 Jefferson Research N/A Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of NEUROGESX INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. 11 $20 View Abstract
24-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: NEUROGESX INC 5 $25 View Abstract
17-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: NEUROGESX INC 5 $25 View Abstract
15-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: NEUROGESX INC 5 $25 View Abstract
30-Mar-09 Market Edge N/A Market Edge Equity Research Report 4 $10 View Abstract
Next 4

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.